In addition, several recent studies have focused on targeting Roquin and Regnase1, negative regulators of T cell activation and differentiation, to enhance the proliferation and persistence of tumor-antigen-specific CD8+ T cells or CAR-T cells and effectively inhibit tumor growth (71, 130–132). Here, CD8A is linked to neoplasm.